Fig. 2.

Targeted phosphoproteomics in MET-positive cancer cell lines. A Heat map displaying shared phosphorylations emerging in the MET-addicted systems EBC-1 and GTL-16 upon exposure to the MET inhibitor tepotinib (MET addiction phosphorylation signature) and their modulation upon METi, IR and their combination 1 or 8 h post IR across the MET-positive cell line cohort. Blue, upregulated phosphopeptides. Red, downregulated phosphopeptides. Dot, adjusted p value < 0.05. B Time-dependent emergence of the MET addiction phosphorylation signature in the MET-addicted system EBC-1 upon METi relative to the apoptotic markers cleaved PARP and Bim-L. Blue, upregulated phosphopeptides. Red, downregulated phosphopeptides. Dot, adjusted p-value < 0.05. C Phosphopeptides commonly regulated in Group I cell lines and displaying significant differences between the treatment by IR and METi + IR